Between The Lines

Expert oncologists review key data from the CRESTONE trial, which observed the safety and efficacy of seribantumab, an anti-HER3 IgG2 monoclonal antibody, in solid tumors with NRG1 fusions.

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.

Stacy A. Cohen, MD, and Mark Lewis, MD review results from the GALAXY study on circulating tumor DNA dynamics in CRC that were recently presented at ASCO GI 2022, and discuss the clinical implications of the findings.

Expert perspectives on recent updates in the use of proteasome inhibitors for patients with multiple myeloma.

A panel of oncologists reviews a publication by Motzer et al. (2021) on data from the CLEAR trial studying lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma treatment and discuss the clinical implications of the results.

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.

Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.